D. Chevrier et al., IDIOPATHIC AND SECONDARY MEMBRANOUS NEPHROPATHY AND POLYMORPHISM AT TAP1 AND HLA-DMA LOCI, Tissue antigens, 50(2), 1997, pp. 164-169
In a previous study on the effects of TAP1 and TAP2 gene polymorphism
in kidney allograft recipients, we found no association between graft
outcome and recipient/donor TAP1 and TAP2 allele polymorphism or compa
tibility, but we observed a surprising increased frequency of the TAP1
0201 allele among kidney recipients. This increase was restricted to
patients with glomerulopathy. We now report on a larger cohort of 178
patients with membranous nephropathy who were typed for their HLA-DPB1
, -DRB1, -DMA, -DMB, LMP2, LMP, TAP1 and TAP2 genes compared with 100
random ethnically matched and healthy unrelated individuals used as co
ntrols. The results show a significant increased frequency of two mark
ers in membranous nephropathy patients as compared with controls: firs
tly the previously recognized increase in HLA-DR3 (59% vs 18%: P-c < 1
X 10(-9), RR = 6.6), secondly a new association with two TAP1 amino a
cid variants displaying respectively a valine in amino acid position 3
33 (TAP1-Val(-333)) and consequently a glycine in position 637 (TAP1Gl
y(-637)) due to its strong linkage disequilibrium with Val(-333). No l
inkage disequilibrium was found between TAP1-Val(-333) and HLA-DR3. Mo
reover, we also noticed a decrease of the DMA0102 phenotype in membra
nous nephropathy patients. The other HLA-DPB, -DMB, LMP2, LMP7 and TAP
2 phenotype frequencies were roughly similar between patients and cont
rols. These results show that the TAP1-Val(-333) like HLA-DR3 phenotyp
e is positively associated with membranous nephropathy and that these
two risk factors are not cumulative in membranous nephropathy pathophy
siology.